Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jun 5;805(1):135-40. doi: 10.1016/j.jchromb.2004.02.036.

Abstract

A high-performance liquid chromatographic (HPLC) assay with UV detection has been developed for the quantitative determination of the antiangiogenic agent SU5416 in human plasma. Sample pretreatment involved a single protein-precipitation step with acetonitrile containing the internal standard, chrysin. Separation of the compounds of interest was achieved on a column packed with HP Zorbax C(8) material (5microm particle size; length: 150mm; i.d.: 4.6mm) using a dual solvent system of 0.01M aqueous ammonium acetate and acetonitrile delivered as a nonlinear gradient at a flow-rate of 1.00ml/min. Simultaneous UV detection was performed at 440nm (SU5416) and 268nm (chrysin). The calibration graph was fit to log-transformed response-concentration data over a range of 10-5000ng/ml. Values for accuracy and precision, obtained from six quality controls analyzed on different days in replicates of 3 or 6, ranged 92.9-109 and 0.8-6.2%, respectively. The developed method was successfully applied to study the pharmacokinetics of SU5416 in a cancer patient receiving the drug as a 1h infusion.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Validation Study

MeSH terms

  • Angiogenesis Inhibitors / blood*
  • Angiogenesis Inhibitors / pharmacokinetics
  • Chromatography, High Pressure Liquid / methods*
  • Female
  • Humans
  • Indoles / blood*
  • Indoles / pharmacokinetics
  • Pyrroles / blood*
  • Pyrroles / pharmacokinetics
  • Reproducibility of Results
  • Spectrophotometry, Ultraviolet / methods*

Substances

  • Angiogenesis Inhibitors
  • Indoles
  • Pyrroles
  • Semaxinib